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Abstract
Background: The relative scale has been used for decades in analysing binary data in epidemiology. In contrast, there
has been a long tradition of carrying out meta-analyses of continuous outcomes on the absolute, original
measurement, scale. The biological rationale for using the relative scale in the analysis of binary outcomes is that it
adjusts for baseline variations; however, similar baseline variations can occur in continuous outcomes and relative effect
scale may therefore be often useful also for continuous outcomes. The aim of this study was to determine whether the
relative scale is more consistent with empirical data on treating the common cold than the absolute scale.
Methods: Individual patient data was available for 2 randomized trials on zinc lozenges for the treatment of the
common cold. Mossad (Ann Intern Med 125:81–8, 1996) found 4.0 days and 43% reduction, and Petrus (Curr Ther Res
59:595–607, 1998) found 1.77 days and 25% reduction, in the duration of colds. In both trials, variance in the placebo
group was significantly greater than in the zinc lozenge group. The effect estimates were applied to the common cold
distributions of the placebo groups, and the resulting distributions were compared with the actual zinc lozenge group
distributions.
Results: When the absolute effect estimates, 4.0 and 1.77 days, were applied to the placebo group common cold
distributions, negative and zero (i.e., impossible) cold durations were predicted, and the high level variance remained.
In contrast, when the relative effect estimates, 43 and 25%, were applied, impossible common cold durations were not
predicted in the placebo groups, and the cold distributions became similar to those of the zinc lozenge groups.
Conclusions: For some continuous outcomes, such as the duration of illness and the duration of hospital stay, the
relative scale leads to a more informative statistical analysis and more effective communication of the study findings.
The transformation of continuous data to the relative scale is simple with a spreadsheet program, after which the
relative scale data can be analysed using standard meta-analysis software. The option for the analysis of relative effects
of continuous outcomes directly from the original data should be implemented in standard meta-analysis programs.
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infections, Statistics, Zinc lozenges
Correspondence: harri.hemila@helsinki.fi
Department of Public Health, POB 20 University of Helsinki, Tukholmankatu 8
B, FI-00014 Helsinki, Finland
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hemilä BMC Medical Research Methodology  (2017) 17:82 
DOI 10.1186/s12874-017-0356-y
Background
In this study, the “absolute scale” indicates comparison
on the scale of the original measurements such as days
in the case of common cold duration. The “relative
scale” indicates comparison with a placebo group level
normalized to 1.0 or 100%.
The relative scale has been used for decades in analysing
binary data in epidemiology. Relative risk (RR) allows the
generalization of effects to different population groups,
such as the 2-fold increase in total mortality and the 10-
fold increase in lung cancer risk with smoking [1, 2].
Meta-analyses of binary outcomes on the relative scale
have led to less heterogeneity than analyses on the abso-
lute scale (risk difference) [3]. In addition, the relative
scale cannot yield negative predicted values, whereas the
absolute scale can.
In contrast, there has been a long tradition of carrying
out meta-analyses of continuous outcomes on the abso-
lute (original measurement) scale as the mean difference
(MD), or using the standard deviation (SD) as the unit
of the scale, which leads to the standardized mean differ-
ence (SMD) scale. Both of these approaches are available
as options in popular meta-analysis software such as the
RevMan program of the Cochrane collaboration [4].
The biological rationale for using the relative scale in
the analysis of binary outcomes is that it adjusts for base-
line variations. However, similar baseline variations can
occur in continuous outcomes. For example, over 100
viruses cause the common cold, and the severity and
duration of symptoms vary by virus. Since the distribution
of viruses varies and different operational common cold
definitions have been used in controlled trials, a substan-
tial variation in the average untreated (placebo group)
common cold duration is to be expected between trials.
Since analysing the effect of treatment on the relative scale
would partly adjust for such baseline variations between
the placebo groups, the relative effect of a treatment on
common cold duration might be more widely generalized
than the absolute effect.
Friedrich et al. compared the absolute and relative
scales in a series of 143 meta-analyses of continuous
outcomes, and found less heterogeneity when the
analysis was carried out on the relative scale [5]. They
introduced the term Ratio of Means (RoM) to describe
the calculation of the relative effect, and used a Taylor
series-based approximation to calculate the SD for the
RoM [5–7].
In our 2004 Cochrane review on vitamin C and the
common cold, we used the relative scale, dividing the
mean and SD of the cold durations of the study groups
by the placebo group mean [8]. This approach is trans-
parent and the SDs and the numbers of participants are
apparent in the forest plots constructed with the stand-
ard programs. The effect estimate is identical with the
RoM, yet the SD differs from that calculated by the
Taylor series-based formula [5].
In epidemiology, the term RR is well established and
the effects are often so large that the RR values are use-
ful in communication. However, the treatment effects
are often rather small and, instead of an RoM value, it
may be more practical to consider treatment effects in
percentages. Obviously, it is mathematically identical to
state either that a treatment has an effect of RoM = 0.75
or that the treatment leads to a 25% reduction in the
outcome. In this study, percentages are mainly used
since they are familiar to most people.
If the relative scale is superior for some continuous
outcomes compared with the absolute (i.e., MD) and the
SMD scales, then the lack of the option of calculating
the relative effect in popular meta-analysis packages
would have led to suboptimal analysis of such outcomes.
Although the calculation of the RoM estimates is simple
on a spreadsheet, many meta-analysts do not consider
approaches outside of the options provided by the stand-
ard programs. Furthermore, poorly selected measures of
treatment effect can also hamper the communication of
results to physicians and patients [5].
In considering the preference for the relative or the ab-
solute scale, a question of fundamental importance is
which of them is more consistent with the empirical data.
The approach of this study was to examine the pre-
dicted effects of zinc lozenges on the placebo group
common cold durations by the absolute effect (in days)
against the relative effect (in percentages). If the relative
effect estimate is better, its application to the observed
placebo group distribution would lead to a distribution
of cold durations that is closer to the zinc lozenge group
distribution. This kind of approach is informative only if
the trial has demonstrated a significant difference be-
tween the treatment groups. This study analyses 2 trials
that found benefit from zinc lozenges and for which
individual patient data (IPD) were available [9, 10].
Methods
Selection of the zinc lozenge trials
No new literature search was done for this analysis.
Several systematic searches of the literature on zinc
lozenges and the common cold have been published
[11–14] and the selection of the 2 trials for this analysis
was based on those searches. The Mossad et al. [9] and
the Petrus et al. [10] trials were selected because individ-
ual patient data (IPD) were available and because both
of them found that zinc lozenges had a significant effect
on common cold duration (Additional file 1). Significant
benefit from zinc lozenges was reported in 2 other trials
which published their results as survival curves. How-
ever, the follow-up was just one week in one of them
and half of placebo patients were censored [15]. In
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another trial, the total number of patients was only 48
[16], half of the number of patients in both of the trials
included [9, 10].
Statistical methods
The Mossad [9] data set was no longer available and it
was regenerated from the published survival curves as
described previously [12] (Additional file 2). In the
Mossad [9] study, there were 2 censored patients in the
zinc lozenge group and 6 in the placebo group. In the
analysis of the distributions of cold duration, the day of
censoring was assumed to be the day of recovery. In the
placebo group, 4 of the 6 censored patients were censored
on day 15 or later. Thus, assuming that the censoring day
was the day of recovery does not inflate the variance in
the placebo group, but may bias it downwards. In the sur-
vival analyses, those patients were classified as censored.
The Petrus [10] data set was kindly made available by Dr.
Petrus; there were no censored patients in that study.
In this study, transformation to the percentage (rela-
tive) scale was done by dividing the means and SDs of
the trial by the placebo group mean, and multiplying by
100% (Table 1). The zinc lozenge group level thus be-
comes the ratio of means (RoM) [5] and the difference
between the zinc and placebo groups gives the effect of
zinc lozenges in percentages directly. As a t-test, this ap-
proach is identical with the t-test of the original values
(i.e., the MD scale), since the transformation is linear.
Other approaches to analyze the relative effect of zinc
lozenges are shown in Additional file 3. The second way
to calculate the 95% CI and the P-value was done by first
log-transforming the cold durations, which makes the
variances of the zinc and placebo groups equal (P > 0.4;
variance test for both trials), but increases skewness in
Mossad’s zinc group, thereafter calculating the t-test on
the log scale, and finally back-transforming to the rela-
tive effect estimate and its 95% CI. The third way to
calculate the 95% CIs was by the Taylor series-based
formula [5]. The fourth way to calculate the 95% CI was
by the Fieller method allowing unequal variances [17].
Finally, the 95% CI was calculated by bootstrap. This
was done on both the normalized scale so that the
placebo group mean was set at 100%, i.e., sampling
[mean(Zn) – mean(Placebo = 100%)], and on the ratio of
the means, i.e., sampling [mean(Zn)/mean(Placebo)].
The R program package [18] was used in the statis-
tical analyses. The similarity of the variance in the zinc
and placebo groups was tested by the var.test proced-
ure. The t-test was calculated by the t.test procedure
(var.equal = False/True). The Fisher-Pitman permuta-
tion test was calculated by the oneway_test procedure
(distribution = exact) of the coin package. The Fieller
95% CIs were calculated with the t.test.ratio procedure
of the mratios package. The bootstrap 95% CIs were
calculated by the boot and boot.ci procedures of the
boot package (type = BCa). Cox regression models were
Table 1 Absolute and relative effects of zinc lozenges in the two randomized trials
Mossad (1996) [9] Petrus (1998) [10]
Trial groups: Zinc Placebo Zinc Placebo
N: 49 50 52 49
Duration of colds
Mean (days): 5.20 9.20 5.29 7.06
SD (days): 2.83 5.32 2.57 3.91
P, variance test to compare the SDs: 2*10−5 0.004
Effect of zinc on the absolute scale (days):
(95% CI):
−4.00
(−5.7 to −2.3)
−1.77
(−3.1 to −0.47)
Quantiles of common cold duration (days)
1st quartile: 3 5 3 4
2nd quartile: 5 8 5 6
3rd quartile: 7 14 7 8
90th percentile: 9 17 8 14
Transformation to the %-scale*:
Mean (% of placebo group mean): 56.6% 100% 74.9% 100%
SD (% of placebo group mean): 30.7% 57.8% 36.4% 55.3%
Effect of zinc on the relative scale:
(95% CI):
−43.4%
(−62% to −24.9%)
−25.1%
(−44% to −6.7%)
* Transformation to the %-scale indicates that the means and SDs of the Mossad [9] study were divided by 9.20 days, and the Petrus [10] study by 7.06 days. By
this transformation the value of the zinc lozenge group mean becomes the RoM and the difference between the zinc and placebo groups gives the effect of zinc
lozenges directly in percentages. Since this transformation is linear, the relative scale leads to a t-score identical with that obtained on the original values (i.e., on
the absolute scale; the MD scale)
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calculated by the coxph procedure, the logrank test by
the survdiff(rho = 0) procedure and the Kaplan-Meier
curves were drawn using the survfit procedure of the
survival package. The calculations are described in
Additional file 4.
Results
This comparison of the absolute scale against the rela-
tive scale in the analysis of the treatment effects on
common cold duration focused on 2 randomized trials;
the zinc gluconate lozenge trial by Mossad et al. [9] and
the zinc acetate lozenge trial by Petrus et al. [10]. Both
trials had close to 100 patients divided equally into their
zinc and placebo groups (Table 1; Additional file 1).
The Mossad [9] trial
Figure 1 shows the number of common cold patients
who recovered on each day of the follow-up in the
Mossad [9] trial. The placebo group is on the top row
and the zinc lozenge group on the bottom row of the
figure. Both distributions appear closer to the uniform
distribution than to the normal distribution. Further-
more, the SD of the placebo group is significantly greater
than the SD of the zinc group (Table 1).
On the absolute scale, zinc lozenges shortened the
duration of colds by 4.0 days. Table 1 shows the trans-
formation of the common cold duration to the relative
scale so that the placebo group is normalized to 100%.
The zinc group level becomes the RoM = 0.566 and the
difference between the zinc and placebo groups directly
indicates a 43.4% reduction in common cold duration
with the zinc lozenges. Since this transformation is linear,
the t-tests for the 2 approaches lead to identical t-
scores and P-values. The relevant question about the pref-
erence for the 2 effect estimates, 4.0 days vs. 43%, is the
divergence in their implications.
If the 4-day reduction in common cold duration is
assumed to be a uniform expected effect over Mossad’s
patients then the 4-day estimate should be valid for both
short and long colds. This implies that the 4-day reduc-
tion in cold duration with zinc lozenges corresponds to
the translocation of the common cold distribution of the
placebo group towards the left by 4.0 days (2nd row in
Fig. 1). The uniform shortening of colds by 4.0 days
predicts that zinc treatment would lead to 12 patients
with a negative or zero cold duration, which are impos-
sible. Such a transformation also retains the high vari-
ance of the placebo group compared with the actual zinc
lozenge group.
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Fig. 1 The observed days of recovery and the transformed placebo group days of recovery in the Mossad [9] study. The first row shows the observed
number of placebo patients who recovered on the day shown on the horizontal axis. The bottom row shows the observed number of zinc lozenge
patients who recovered on the given day. The SDs of the placebo and zinc lozenge groups are significantly different with P = 2*10−5. The second row
shows the transformation in which each placebo group common cold is assumed to become 4.0 days shorter because of the effect of the zinc
lozenges. The third row shows the transformation in which each placebo group common cold is assumed to become 43% shorter because of the zinc
lozenges. In the Mossad study, 2 patients were censored in the zinc group on days 9 and 11; and 6 patients were censored in the placebo group on
days 7, 15, 16, and 19. The day of censoring was assumed to be the day of recovery in this figure
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If the 43% reduction in common cold duration is
assumed to be a uniform relative effect over Mossad’s
patients, this indicates that multiplication of the cold
durations of the placebo group by 0.57 should lead to a
distribution similar to the distribution of the zinc group
(3rd and 4th rows in Fig. 1). The 43% shortening of
colds in the placebo group does not predict impossible,
i.e., negative or zero, cold durations and the SD of this
predicted distribution is consistent with the SD of the
actual zinc lozenge group (variance test P = 0.7).
The absolute and relative effects can also be compared
on the basis of the quartiles of the cold distributions in
the treatment groups (Table 1). The ratios for the 1st, 2nd
and 3rd quartiles of the zinc and placebo groups indicate
reductions in common cold duration by 40, 38 and 50%
respectively with zinc lozenges, which are all close to the
overall 43% estimate. In contrast, the absolute differ-
ences in the quartiles of the 2 groups are 2, 3 and
7 days, which have a much greater variation around
the absolute effect estimate of 4.0 days. For the 90th
percentiles of cold duration, the bootstrap 95% CI for
the absolute difference between the zinc and placebo
groups is from −11 to −5.6 days, which does not in-
clude the overall −4.0 day estimate. In contrast, the
bootstrap of the ratio of the 90th percentiles gives a
95% CI from −58 to −31%, which is consistent with
the overall estimate of −43%.
Survival analysis is a further informative way to examine
the time of recovery. The Kaplan-Meier plots for the zinc
group and the 43% shortened placebo group cold dura-
tions are closely overlapping (Fig. 2). Cox regression gives
an estimate of RR = 2.7 for the effect of zinc lozenges.
The Petrus [10] trial
Figure 3 shows the number of patients recovering on
each day in the Petrus [10] trial. Here too the distribu-
tions of colds in the placebo and zinc groups appear
close to the uniform distribution and the SD is signifi-
cantly greater in the placebo group than the zinc group
(Table 1). Zinc lozenges shortened the duration of colds
by 1.77 days on the absolute scale and by 25% on the
relative scale (Table 1).
The 1.77-day uniform shortening of colds in the pla-
cebo group predicts that 3 colds will last just for 0 days
(2nd row in Fig. 3) and retains the high variance com-
pared with the actual zinc lozenge group. In contrast,
the 25% shortening of colds in the placebo group leads
to a cold distribution similar to the zinc lozenge group
(3rd and 4th rows of Fig. 3), and to a SD consistent with
that of the zinc group (variance test P = 0.4).
The quartiles of duration in the Petrus [10] trial are
not informative for the comparison of the absolute and
relative scales. However, the difference between the zinc
and placebo groups at the 90th percentile level of
duration, −43% and −6 days, is more consistent with the
relative effect estimate of −25% compared with the abso-
lute effect estimate of −1.77 days (Table 1). For the 90th
percentiles, the bootstrap 95% CI for the difference be-
tween the groups is from −8 to −4.5 days, which is far
from the overall estimate of −1.77 days. In contrast, the
bootstrap of the ratio of the 90th percentiles gives a 95%
CI from −53 to −33%, which is much closer to the overall
estimate of −25%.
The Kaplan-Meier plots for the zinc group and the
25% shortened placebo group colds overlap closely
(Fig. 4). Cox regression gives an estimate of RR = 1.77
for the rate of recovery in the zinc lozenge group com-
pared with the placebo group.
Comparison of methods available to calculate the P-values
and the 95% CIs for relative effects
Given that the relative scale appears better in the ana-
lysis of common cold duration, different approaches to
calculate the P-values and the 95% CIs for relative effects
were compared (Additional file 3). Since both trials had
Fig. 2 Survival curves for the treatment groups and for the 43%
shortened placebo group cold durations for the Mossad [9] study. The
solid curve indicates the zinc lozenge group, the dashed curve on the
right hand side indicates the placebo group, and the dotted curve
overlapping the zinc lozenge curve indicates the recovery curve
obtained by shortening all the placebo group common cold durations
by 43%. The difference between the placebo group and the zinc
lozenge group is significant, P = 10−5 on the logrank test, whereas
there is no difference between the zinc lozenge group and the 43%
shortened placebo group common cold durations (P = 0.8). The 4.0-
day shortened placebo group colds (2nd row in Fig. 1) would lead to a
survival curve starting to decline before day 0 and crossing the zinc
group curve. To keep this figure less confusing that curve is not
shown. Cox regression model indicates that zinc lozenges increased
the rate of recovery by RR = 2.7 (95% CI 1.7 to 4.4)
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significant differences in the variances between the zinc
lozenge and placebo groups, the t-test was calculated
assuming equal variance and allowing unequal variance,
but the difference in the P-values was minor. The non-
parametric Fisher-Pitman permutation test and the log-
rank test gave P-values essentially identical with those by
the t-tests. For both trials, the t-test of log-transformed
cold durations yielded conservative P-values compared
with the P-values calculated with the permutation and
logrank tests. The 95% CIs calculated with the relative
scale approach used in this study were more conserva-
tive than the 95% CIs calculated by the Taylor series
approach [5] and by the Fieller approach [17].
Discussion
If a treatment consistently has no effect at all, the scale of
the meta-analysis probably matters little. However, if a
treatment does have an effect, the scale may substantially
influence the interpretation of the findings and the com-
munication about them. Therefore this analysis selected 2
trials that found a significant benefit from zinc lozenges
and for which IPD was available. While the goal of this
study was not to estimate the overall effect of zinc loz-
enges on common cold duration, the findings in these 2
trials are consistent with the relative effects (i.e., the %
decrease) found in 4 other trials on zinc lozenges [12, 19].
When the effect of zinc lozenges on cold duration was
estimated on the absolute scale, i.e., as the number of days
by which the colds became shorter, applying the effect
estimates to the placebo group cold distribution yielded
impossible, negative or zero, predicted durations for colds.
In addition, the distributions remained wide compared
with the distributions in the actual zinc lozenge groups. In
contrast, when the relative effect estimate was applied to
the placebo group cold distributions, no impossible com-
mon cold durations were predicted, and the cold distribu-
tions became similar to those of the zinc lozenge groups.
Calculation of the relative effect on common cold dur-
ation is conceptually consistent with the RR calculated
by Cox regression. Nevertheless, the estimates should
not be expected to be reciprocals since the RR depends
on the shapes of the curves, which can differ substan-
tially even though the mean durations remain invariant.
Compared with the t-test, survival analysis is a superior
way to analyse the recovery rate at the level of individual
studies (Figs. 2 and 4), since it allows visual inspection
and formal analysis of time-dependent changes in the
treatment effect, and is not hampered by censored data
or outlier patients who have exceptionally long colds. In
contrast, outliers lead to inflation of the SD estimates in
the t-test and may decrease the power to demonstrate
an effect. However, since only the means and SDs of the
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Fig. 3 The observed days of recovery and the transformed placebo group days of recovery in the Petrus [10] study. The first row shows the
observed number of placebo patients who recovered on the day shown on the horizontal axis. The bottom row shows the observed number of
zinc lozenge patients who recovered on the given day. The SDs of the placebo and zinc lozenge groups are significantly different with P = 0.004.
The second row shows the transformation in which each placebo group common cold is assumed to become 1.77 days shorter because of the
effect of the zinc lozenges. The third row shows the transformation in which each placebo group common cold is assumed to become 25%
shorter because of the zinc lozenges
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study groups are usually published, survival analysis is
rarely an option in the meta-analysis of disease duration.
Therefore, in the meta-analyses of time data the usual
question is about whether the absolute (i.e., MD) scale
or the relative scale is more reasonable for the t-test.
The selection of scale is important in 2 respects. First,
the scale is important when several studies are pooled in
a meta-analysis, since one scale can lead to less hetero-
geneity than another, indicating better capture of the
effect by the former scale [3]. Second, the scale influ-
ences the communication about the findings of single
trials and of meta-analyses.
There has been substantial variation in the mean dur-
ation of untreated (placebo group) colds between trials.
In our Cochrane review on vitamin C and the common
cold, the shortest mean duration of placebo group colds
in trials with children was 2.8 days, whereas the longest
was 14 days [20, 21]. Because the untreated colds differ
so greatly, a 1-day effect has a very different meaning in
those two trials, even though the nominal value of the
effect is the same. Furthermore, with an effective treat-
ment, the 14-day colds might be shortened by a week,
whereas such an effect does not exist on the 2.8-day
scale of the former trial. Thus, the absolute scales of
those two trials are incompatible. Therefore, we have
used the relative scale in our Cochrane review on vita-
min C and the common cold since 2004 [8, 20]. There
has also been a substantial variation in cold durations in
the placebo groups of 11 zinc lozenge studies, from 5 to
10 days [12].
There is evidence from studies on vitamin C and the
common cold that heterogeneity in treatment effect may be
lower on the relative scale. In 14 trials on vitamin C for
children, the relative scale (i.e., the %-scale) pooling led to
I2 = 27% (P = 0.17) for the heterogeneity in the treatment ef-
fects, whereas heterogeneity in the days-scale was I2 = 46%
(P = 0.03). Less heterogeneity may lead to stronger evidence
of treatment effect and, as expected, the pooled treatment
effect on the relative scale was stronger (Z = 4.04) than on
the absolute scale (Z = 3.11) [21]. An earlier meta-analysis
of vitamin C and the common cold studies also
pointed out that the relative scale led to a stronger
evidence of treatment effect (P = 0.001) than the abso-
lute scale (P = 0.01) [22]. These differences indicate
that the relative scale may capture the effects of treatments
on common cold duration better.
The selection of scale is also important in the commu-
nication of the findings. In the placebo groups of the in-
cluded trials, the duration of the common colds ranged
from 2 to 19 days in the Mossad [9] trial, and from 2 to
15 days in the Petrus [10] trial. Such a great variation in
the durations of untreated colds should be taken into
account in communication. The 43 and 25% effects are
applicable over the whole range of the untreated cold
durations. In contrast, claims that zinc shortens the dur-
ation of colds by 4.0 or 1.77 days according to the two
trials analyzed (Table 1), or by 1.65 or 1.03 days accord-
ing to two meta-analyses [13, 14], have a very different
meaning depending on whether the assumed untreated
cold episode might last for 2 days or 2 weeks. If only
one type of estimate is used in the communication, the
relative effect appears to be much more informative
since it is applicable to the entire range of potential
episode durations. Nevertheless, both measures may be
shown in parallel.
The SMD scale is a third approach that has been used
to estimate the magnitude of treatment effect on continu-
ous outcomes [4, 5]. This normalizes the observations so
that one unit on the scale corresponds to one unit of SD
in each trial included in the meta-analysis. Such a scale is
confusing for an ordinary reader. For example, the 2011
Cochrane review on zinc and the common cold stated in
its abstract that the “intake of zinc is associated with a
significant reduction in the duration (standardised mean
difference (SMD) -0.97)” [23]. Reporting should always
show the unit of measurement, and this sentence should
have been written more accurately as: “zinc shortened the
duration of colds by 0.97 SD units”. However, such
Fig. 4 Survival curves for the treatment groups and for the 25%
shortened placebo group cold durations for the Petrus [10] study.
The solid curve indicates the zinc lozenge group, the dashed curve
on the right hand side indicates the placebo group, and the dotted
curve overlapping the zinc lozenge curve indicates the recovery
curve obtained by shortening all the placebo group common cold
durations by 25%. The difference between the placebo group and
the zinc lozenge group is significant, P = 0.006 on the logrank test,
whereas there is no difference between the zinc lozenge group and
the 25% shortened placebo group common cold durations (P = 0.9).
Cox regression model indicates that zinc lozenges increased the rate
of recovery by RR = 1.77 (95% CI 1.16 to 2.7)
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accurate reporting would have revealed the main prob-
lem of the SMD scale: what does the SD unit mean in
practical terms. Most physicians and patients can con-
sider whether 42 or 25% is a small or a large effect, but
few of them can form their own opinion about whether
an effect of 0.97 SD units is small or large. In this re-
spect, the relative scale is far superior in the communi-
cation of findings to physicians and patients, since they
have long-term familiarity with the percentage effects.
The difficulty of communicating the SMD findings to
patients has been pointed out [5, 24].
The SMD scale is extensively used. However, its usage
does not seem to originate from biological or statistical
considerations, but from the fact that, along with the
MD scale, it is the only option that is available in the
popular statistical software for meta-analysis, such as the
RevMan of Cochrane Collaboration [4]. Thus, the wide
availability of the SMD option guides researchers to use
it without them considering the biological issues prop-
erly, or the difficulties in communicating the findings on
that scale [5, 24].
Based on 143 meta-analyses on continuous outcomes,
Friedrich et al. concluded that there was less heterogen-
eity in the meta-analyses when they were carried out on
the relative scale [5]. Although their findings support the
preference for the relative scale, they did not consider
the diversity of the kinds of outcomes that are measured
by continuous outcomes. It seems evident that the rela-
tive scale is superior for some outcomes such as the dur-
ation of the common cold and other diseases, whereas
the absolute scale may be superior for some other out-
comes. Therefore diverse continuous outcomes should
not be combined into a uniform mass, so that all of
them are calculated on the relative scale and compared
with all of them on the absolute scale.
Essential requirements for using the relative scale in
a meta-analysis appear to be that the measurements
can be transformed so that the control group means
are 100%, and that there is a relevant and unambigu-
ous target level of 0%. However, there are many types
of continuous outcomes which do not have a relative
scale that is relevant. For example, since blood pres-
sure does not have either a reasonable 100% level
over various trials, or a reasonable 0% target level,
pooling studies and reporting effects on blood pres-
sure on the percentage scale might lead to confusions.
The mmHg scale (absolute scale) stratified by the
pre-treatment mmHg level may be preferable. An-
other example where percentage scale would lead to
confusions is measuring body temperature. If a pa-
tient has fever, it is more informative to describe how
many degrees the fever was reduced, rather than
describing the relative decrease in body temperature
on the Kelvin scale.
The duration of the common cold was used as a
model of continuous outcomes. The common cold is by
itself a clinically relevant topic as reflected, for example,
by the existence of 18 Cochrane reviews in which the
title includes the term [25]. Furthermore, it seems evi-
dent that the findings of this study apply to many other
continuous outcomes that measure time, such as the
duration of other diseases, and the duration of hospital
stay and intensive care unit stay, etc.
In this study, the transformation to the relative scale
was done by dividing the mean and SD values by the pla-
cebo group mean value, which transforms the zinc group
mean level to the RoM and keeps the ratios of SDs and
means identical with their ratios on the absolute scale.
This approach is transparent but more conservative than
the Taylor series approach [5] and the Fieller approach
[17], see Additional file 3. These approaches should be
compared to find out which is the most useful in meta-
analyses.
Conclusions
The choice between the absolute scale and the relative
scale should be determined on the basis of biological
reasoning and on the basis of testing which scale leads
to less heterogeneity. The relative scale option should be
made available for the standard meta-analysis software,
but meanwhile the transformation to the relative scale
can be easily calculated with spreadsheet programs, and
the transformed data can be analyzed with standard
meta-analysis software.
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